Cholesterol Levels Drop During Cancer Immunotherapy with IL-2
Author Information
Author(s): P. Lissonil, F. Brivio, S. Pittalis, M.S. Peregol, A. Ardizzoia, O. Mauri, S. Barnil, S. Crispinol, G. Tancinil
Primary Institution: Hospital of Monza, San Raffaele Hospital, Milan, Italy
Hypothesis
Does IL-2 therapy affect cholesterol metabolism in cancer patients?
Conclusion
IL-2 therapy significantly lowers cholesterol levels in hypercholesterolemic cancer patients.
Supporting Evidence
- Cholesterol levels normalized in 10 out of 10 hypercholesterolemic patients within 7 days of IL-2 therapy.
- LDL-/HDL-cholesterol ratio significantly decreased during IL-2 therapy.
- Triglyceride levels increased during IL-2 therapy, but not significantly.
Takeaway
When cancer patients receive a treatment called IL-2, their cholesterol levels go down quickly, which is good for their health.
Methodology
14 advanced cancer patients received subcutaneous IL-2 therapy, and cholesterol levels were measured at various time points.
Limitations
The study only included a small number of patients and focused on specific types of cancer.
Participant Demographics
11 males and 3 females, median age 56 years (range 24-72), with renal and colon carcinoma.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website